Literature DB >> 28814462

18F-AV-1451 binds to motor-related subcortical gray and white matter in corticobasal syndrome.

Hanna Cho1, Min Seok Baek1, Jae Yong Choi1, Seung Ha Lee1, Joong Seok Kim1, Young Hoon Ryu1, Myung Sik Lee1, Chul Hyoung Lyoo2.   

Abstract

OBJECTIVE: To investigate tau distribution in patients with corticobasal syndrome (CBS) using 18F-AV-1451 PET.
METHODS: Six consecutively recruited patients with CBS and 20 age-matched healthy controls underwent 2 PET scans with 18F-AV-1451 (for tau) and 18F-florbetaben (for β-amyloid). We compared standardized uptake value ratio maps of the 18F-AV-1451 PET images between the patients with CBS and controls.
RESULTS: Compared to controls, patients with CBS exhibited asymmetrically increased 18F-AV-1451 binding in the putamen, globus pallidus, and thalamus contralateral to the clinically more affected side and in the ipsilateral globus pallidus and dentate nucleus. Voxel-based comparison additionally showed asymmetrically increased 18F-AV-1451 binding in the focal regions of the precentral gray and white matter and in the midbrain, predominantly in the contralateral side. 18F-AV-1451 binding in the precentral white matter correlated with motor severity.
CONCLUSIONS: 18F-AV-1451 asymmetrically binds to motor-related subcortical gray and white matter structures in patients with CBS. This pattern corresponds to tau pathology distribution in postmortem studies, and motor deficit in patients with CBS may be associated with tau accumulation predominantly in the subcortical white matter underlying the motor cortex, leading to disruptions in motor-related networks.
© 2017 American Academy of Neurology.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28814462     DOI: 10.1212/WNL.0000000000004364

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  27 in total

1.  18F-AV-1451 positron emission tomography in neuropathological substrates of corticobasal syndrome.

Authors:  Anna E Goodheart; Joseph J Locascio; Wesley R Samore; Jessica A Collins; Michael Brickhouse; Aaron Schultz; Alexandra Touroutoglou; Keith A Johnson; Matthew P Frosch; John H Growdon; Bradford C Dickerson; Stephen N Gomperts
Journal:  Brain       Date:  2021-02-12       Impact factor: 13.501

2.  [18F]-AV-1451 tau PET imaging in Alzheimer's disease and suspected non-AD tauopathies using a late acquisition time window.

Authors:  Julien Lagarde; Pauline Olivieri; Fabien Caillé; Philippe Gervais; Jean-Claude Baron; Michel Bottlaender; Marie Sarazin
Journal:  J Neurol       Date:  2019-09-18       Impact factor: 4.849

3.  [18F] AV-1451 uptake in corticobasal syndrome: the influence of beta-amyloid and clinical presentation.

Authors:  F Ali; J L Whitwell; P R Martin; M L Senjem; D S Knopman; C R Jack; V J Lowe; R C Petersen; B F Boeve; K A Josephs
Journal:  J Neurol       Date:  2018-03-01       Impact factor: 4.849

4.  Corticobasal degeneration: key emerging issues.

Authors:  F Ali; K A Josephs
Journal:  J Neurol       Date:  2017-10-23       Impact factor: 4.849

5.  Tau-PET imaging with [18F]AV-1451 in primary progressive apraxia of speech.

Authors:  Rene L Utianski; Jennifer L Whitwell; Christopher G Schwarz; Matthew L Senjem; Nirubol Tosakulwong; Joseph R Duffy; Heather M Clark; Mary M Machulda; Ronald C Petersen; Clifford R Jack; Val J Lowe; Keith A Josephs
Journal:  Cortex       Date:  2018-01-02       Impact factor: 4.027

6.  Sensitivity-Specificity of Tau and Amyloid β Positron Emission Tomography in Frontotemporal Lobar Degeneration.

Authors:  Alma Ghirelli; Nirubol Tosakulwong; Stephen D Weigand; Heather M Clark; Farwa Ali; Hugo Botha; Joseph R Duffy; Rene L Utianski; Marina Buciuc; Melissa E Murray; Sydney A Labuzan; Anthony J Spychalla; Nha Trang Thu Pham; Christopher G Schwarz; Matthew L Senjem; Mary M Machulda; Matthew Baker; Rosa Rademakers; Massimo Filippi; Clifford R Jack; Val J Lowe; Joseph E Parisi; Dennis W Dickson; Keith A Josephs; Jennifer L Whitwell
Journal:  Ann Neurol       Date:  2020-09-12       Impact factor: 10.422

Review 7.  The Role of Tau Imaging in Parkinsonian Disorders.

Authors:  Jochen Hammes; Alexander Drzezga; Thilo van Eimeren
Journal:  Curr Neurol Neurosci Rep       Date:  2018-10-06       Impact factor: 5.081

8.  18F-flortaucipir PET to autopsy comparisons in Alzheimer's disease and other neurodegenerative diseases.

Authors:  David N Soleimani-Meigooni; Leonardo Iaccarino; Renaud La Joie; Suzanne Baker; Viktoriya Bourakova; Adam L Boxer; Lauren Edwards; Rana Eser; Maria-Luisa Gorno-Tempini; William J Jagust; Mustafa Janabi; Joel H Kramer; Orit H Lesman-Segev; Taylor Mellinger; Bruce L Miller; Julie Pham; Howard J Rosen; Salvatore Spina; William W Seeley; Amelia Strom; Lea T Grinberg; Gil D Rabinovici
Journal:  Brain       Date:  2020-12-05       Impact factor: 13.501

9.  In vivo [18F]-AV-1451 tau-PET imaging in sporadic Creutzfeldt-Jakob disease.

Authors:  Gregory S Day; Brian A Gordon; Richard J Perrin; Nigel J Cairns; Helen Beaumont; Katherine Schwetye; Cole Ferguson; Namita Sinha; Robert Bucelli; Erik S Musiek; Nupur Ghoshal; Maria R Ponisio; Benjamin Vincent; Shruti Mishra; Kelley Jackson; John C Morris; Tammie L S Benzinger; Beau M Ances
Journal:  Neurology       Date:  2018-02-07       Impact factor: 9.910

10.  Tau Imaging in Parkinsonism: What Have We Learned So Far?

Authors:  Jennifer L Whitwell
Journal:  Mov Disord Clin Pract       Date:  2017-12-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.